| Literature DB >> 35745023 |
Emilija Ivanova Stojcheva1, José Carlos Quintela1.
Abstract
Rhodiola rosea L. has a long history of use in traditional medicine to stimulate the nervous system, treat stress-induced fatigue and depression, enhance physical performance and work productivity and treat gastrointestinal ailments and impotence. Apart from its well-established traditional use, a significant number of publications on the clinical efficacy of various R. rosea preparations can be found in the literature. The majority of these studies are related to the efficacy of R. rosea in terms of cognitive functions and mental performance, including various symptoms of life-stress, fatigue and burnout. The beneficial effects of this medicinal plant on enhancing physical performance have also been evaluated in professional athletes and non-trained individuals. Moreover, even though most evidence originates from pre-clinical trials, several clinical studies have additionally demonstrated the remediating effects of R. rosea on cardiovascular and reproductive health by addressing non-specific stress damage and reversing or healing the disrupted physiologies and disfunctions. Overall, in accordance with its aim, the results presented in this review provide an encouraging basis for the clinical efficacy of R. rosea preparations in managing various aspects of stress-induced conditions.Entities:
Keywords: Rhodiola rosea; adaptogen; clinical studies; golden root; medicinal plants; phytotherapy; roseroot; stress protection
Mesh:
Substances:
Year: 2022 PMID: 35745023 PMCID: PMC9228580 DOI: 10.3390/molecules27123902
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Main phytochemicals identified in Rhodiola rosea L.
| Group of Compounds | Compound |
|---|---|
| Phenylpropanoids | rosavin, rosin, rosarin |
| Phenylethanoid derivatives | |
| Flavanoids | rhodiolin, rhodionidin, rhodionin, rhodiosin, rhodalidin, tricin |
| Monoterpene derivatives | rosiridol, rosiridin, rhodiolosides A–E |
| Triterpenes | daucosterol, beta-sitosterol |
| Phenolic acids | chlorogenic acid, hydroxycinnamic acid, gallic acid |
Relevant clinical trials on the effects of Rhodiola rosea L on mental and physical performance.
| Reference | Study Design | Condition | Participants | Intervention | Control | Duration | Outcome Measures | Results |
|---|---|---|---|---|---|---|---|---|
| Darbinyan (2000) | randomized, placebo-controlled, double-blind, crossover with a wash-out period | Work-related fatigue | 56 healthy male and female physicians aged 24–35 | 170 mg of | Placebo | 42 days total duration; | Overall level of mental fatigue calculated according to the Fatigue Index, involving complex perceptive and cognitive cerebral functions | A statistically significant improvement in the Fatigue Index observed in the |
| Edwards (2012) | multicentre, non-randomized, open-label, single-arm study conducted in 13 centres in UK | Life-stress symptoms | 101 ambulatory subjects between 30 and 60 years of age with life-stress symptoms | 200 mg of | None | 4 weeks | (1) Numerical Analogue Scales (NAS) of subjective stress Symptoms; | All outcome variables showed consistent and steady improvements with regard to stress symptoms, fatigue, quality of life, mood, concentration, disability, functional impairment and overall therapeutic effect. A statistically significant improvement between baseline and week 4 based on the two-sided Wilcoxon signed-rank test was observed |
| Spasov (2000) | randomized, double-blind, placebo-controlled, 2 parallel groups study | Non-specific fatigue and stress during examination | 40 healthy medical students, 17–19 years old | 50 mg of | Placebo | 20 days | Physical fitness measured as: physical work capacity and an increase in pulse rate, neuro-motoric fitness, mental work capacity, self-evaluation of fatigue and general well-being | The students receiving |
| Spasov (2000) | randomized, placebo-controlled, 3 parallel groups study | Study-related fatigue and stress | 60 healthy male students, 17–18 years old | 660 mg of | Placebo and untreated | 20 days | Psychological fatigue, situational anxiety, motivation, precision of motor function, process of excitement, need for rest, mental work capacity and neuromotor function | An increase in physical work capacity, coordination, kinaesthetic sensitivity, and general well-being, along with a decrease in fatigue and situational anxiety observed in the |
| Shevtsov (2003) | randomized, double-blind, placebo-controlled, parallel-group study with an extra non-treatment group | Work-related fatigue and stress | 161 healthy cadets, 19–21 years old | (1) 370 mg of | Placebo and untreated | Single dose | Total Antifatigue Index (TAFI) calculated by two efficacy parameters: capacity for mental work, physiological parameters and safety parameters | A pronounced anti-fatigue effect reflected in the TAFI found in both |
| Schutgens (2009) | randomized, double-blind, placebo-controlled, 3 parallel groups study | Experienced levels of stress and fatigue | 30 healthy students; mean age: 21.1 years | 144 mg of SHR-5 | Placebo and ADAPT-232 | 7 days | (1) Ultra-weak photon emission; | A statistically significant decrease in the experienced level of fatigue and decreased photon emission observed in the |
| Goyvaerts (2012) | open-label design | Burnout and fatigue syndrome | 330 female (74%) and male (26%) patients between 18 and 81 years | 288 mg of | None | 8 weeks | Total burnout score: | The |
| Olsson (2009) | randomized, double-blind, placebo-controlled, parallel group study | Fatigue syndrome | 60 patients diagnosed with fatigue syndrome; mean age: | 144 mg of | Placebo | 28 days | (1) Fatigue (Pines’ burnout scale); | A notable anti-fatigue effect that increased mental performance, particularly the ability to concentrate and decreased cortisol response to awakening stress in burnout patients. |
| Lekomtseva (2017) | open-label, single-arm, multicentre study conducted in 5 hospitals in Ukraine | Prolonged or chronic fatigue | 100 subjects, 31 male, 69 female | 200 mg of | None | 8 weeks | (1) Multidimensional Fatigue Inventory 20 (MFI-20); | A significant improvement in prolonged or chronic fatigue symptoms over 8 weeks. The values of nearly all outcome variables markedly improved over time, with a substantial alleviation of symptoms that could already be observed after the first week of treatment. |
| Kasper (2017) | exploratory, open-label, multicentre, single-arm trial conducted at four centres in Vienna, Austria | Burnout symptoms | 118 outpatients aged 30–60 years suffering from burnout symptoms | A daily dose of 400 mg | None | 12 weeks | (1) Maslach Burnout Inventory; | The majority of the outcome measures showed clear improvements over time. A steady and substantial, statistically relevant alleviation of the majority of the assessed burnout symptoms was observed as early as 1 week after the start of treatment. |
| Bystritsky (2008) | open-label design | Generalized anxiety disorder (GAD) | 10 participants with a DSM-IV diagnosis of GAD between the ages of 34 and 55 | 340 mg of | None | 10 weeks | (1) HARS; | Significant improvements in GAD symptoms were found with |
| Cropley (2015) | open-label, randomized, repeated measures design | Self-reported anxiety, stress, cognition, and other mood symptoms | 81 mildly anxious students randomized into one of two conditions: treatment = 40; control = 41 volunteers | 2 × 200 mg of a dry extract from | Untreated | 14 days | Primary outcomes: | The experimental group demonstrated a significant |
| Darbinyan (2007) | randomized, double-blind, placebo-controlled study with 3 parallel groups | Mild to moderate depression | 89 male and female patients diagnosed with mild or moderate depression, age 18–70 years | 2 groups: | Placebo | 6 weeks | (1) Beck Depression Inventory (BDI); | Overall depression, insomnia, emotional instability and somatization significantly improved following medication. |
| Mao (2015) | randomized, double-blind, placebo-controlled study with 3 parallel groups | Mild to moderate major depressive disorder (MDD) | 57 male and female patients: | (1) 340 mg of | Placebo | 12 weeks | (1) Hamilton Depression Rating (HAM-D); | Patients taking |
| Gao (2020) | randomized, double-blind, placebo-controlled study with 3 parallel groups | Mild to moderate major depressive disorder (MDD) | 100 patients (33/33/34) with a DSM IV Axis I diagnosis of MDD aged 18–50 years | (A) sertraline | Placebo | 12 weeks | (1) Hamilton Depression Rating (HAM-D); | Statistically significant reductions in HAM-D, BDI, and CGI scores for all treatment conditions. The decline in HAM-D, BDI, and CGI scores was greater for group B versus group C and A. |
| Williams (2021) | placebo-controlled, double-blind, counterbalanced, crossover study | Resistance exercise performance | 10 resistance-trained males | 1500 mg/day standardized | Placebo | 3 days | (1) Performance during repeated bench press exercise; | |
| Noreen (2013) | randomized, placebo-controlled, double-blind, crossover study | Endurance exercise performance, perceived exertion, mood and cognitive function | 18 recreationally active college women (22 ± 3.3 years, 56.6 ± 6.2 kg) | 3 mg·kg−1 of standardized | Placebo | Single dose | (1) Rating of perceived exertion (RPE) (10-point Borg scale); | |
| Duncan (2014) | placebo-controlled, double-blind, crossover study | Exercise performance, substrate utilisation, mood State, and rating of perceived exertion | Ten males, recreational exercisers (mean age ± S.D. = 26 ± 6 years) | 3 mg⋅kg−1 body mass of | Placebo | Single dose | (1) Two 30-m cycling trials at an intensity of 70% of VO2 max; | Ingestion of |
| Jowko (2016) | randomized, double-blind, placebo-controlled trial | Mental and physical performance, hormonal and oxidative stress biomarkers | 26 healthy, male, physical -education students (13/13) | 600 mg of standardized | Placebo | 4 weeks | (1) Psychomotor tests for simple and choice reaction time—Vienna Test System; | |
| Ballman (2018) | randomized, blinded, placebo-controlled and counterbalanced study | Anaerobic exercise performance | 11 physically active female participants, aged 18 to 24 years | 1500 mg/day standardized | Placebo | 3 days | 3 × 15 second Wingate Anaerobic Tests (WAnTs)—mean watts, anaerobic capacity, anaerobic power, mean peak watts, and mean total work | All WAnTs outcome measures were higher in the |
| De Bock (2004) | randomized, placebo-controlled, double-blind, crossover study | Improvement in endurance exercise performance | 24 healthy and physically active male and female students (12/12), mean age: male—21.8 years, female—20.2 years | 2 capsules containing 100 mg of standardized | Placebo | Phase I: 2 days | (1) Endurance exercise capacity; | Time to exhaustion, O2 uptake and CO2 output significantly improved in the |
SHR-5: dry extract of root and rhizome of Rhodiola rosea L., drug-extract-ratio 2.5–5:1, first extraction solvent ethanol 70%, second extraction solvent water. Abbreviations: HAM-D—Hamilton Depression Rating; HARS—Hamilton Anxiety Rating Scale; CGI—Clinical Global Impressions, TAFI—Total Antifatigue Index; SDS—Sheehan Disability Scale; PSQ—Perceived Stress Questionnaire; NTC—Number Connection Test; MDMQ—Multidimensional Mood State Questionnaire; NAS—Numerical Analogue Scales; BDI—Beck Depression Inventory; RPE—rating of perceived exertion; WAnTs—Wingate Anaerobic Tests; POMS—Profile of Mood States.